Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities

被引：69

作者：

Liu, Yubin ^{[1
,2
]}

Cao, Wei ^{[1
,2
]}

Sun, Ming ^{[3
,4
]}

Li, Taisheng ^{[1
,2
,5
,6
]}

机构：

[1] Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Infect Dis, Beijing, Peoples R China

[2] Chinese Acad Med Sci, Beijing, Peoples R China

[3] Chinese Acad Med Sci, Inst Med Biol, Kunming, Yunnan, Peoples R China

[4] Yunnan Key Lab Vaccine Res & Dev Severe Infect Di, Kunming, Yunnan, Peoples R China

[5] Chinese Acad Med Sci, Clin Immunol Ctr, Beijing, Peoples R China

[6] Tsinghua Univ, Med Coll, Beijing, Peoples R China

来源：

EMERGING MICROBES & INFECTIONS | 2020年 / 9卷 / 01期

基金：

中国国家自然科学基金;

关键词：

HIV-1; broadly neutralizing antibodies (bNAbs); efficacies; challenges; opportunities; IMMUNODEFICIENCY-VIRUS TYPE-1; MONOCLONAL-ANTIBODIES; T-CELLS; THERAPY; INFECTION; SPREAD; PROTECTION; RESISTANT; IDENTIFICATION; REPLICATION;

D O I：

10.1080/22221751.2020.1713707

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Combination antiretroviral therapy (cART) is effective but not curative, and no successful vaccine is currently available for human immunodeficiency virus-1 (HIV-1). Broadly neutralizing antibodies (bNAbs) provide a new approach to HIV-1 prevention and treatment, and these promising candidates advancing into clinical trials have shown certain efficacies in infected individuals. In addition, bNAbs have the potential to kill HIV-1-infected cells and to affect the course of HIV-1 infection by directly engaging host immunity. Nonetheless, challenges accompany the use of bNAbs, including transient suppression of viraemia, frequent emergence of resistant viruses in rebound viraemia, suboptimal efficacy in virus cell-to-cell transmission, and unclear effects on the cell-associated HIV-1 reservoir. In this review, we discuss opportunities and potential strategies to address current challenges to promote the future use of immunotherapy regimens.

引用

页码：194 / 206

页数：13

共 88 条

[11] Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys [J].

Barouch, Dan H. ;

Whitney, James B. ;

Moldt, Brian ;

Klein, Florian ;

Oliveira, Thiago Y. ;

Liu, Jinyan ;

Stephenson, Kathryn E. ;

Chang, Hui-Wen ;

Shekhar, Karthik ;

Gupta, Sanjana ;

Nkolola, Joseph P. ;

Seaman, Michael S. ;

Smith, Kaitlin M. ;

Borducchi, Erica N. ;

Cabral, Crystal ;

Smith, Jeffrey Y. ;

Blackmore, Stephen ;

Sanisetty, Srisowmya ;

Perry, James R. ;

Beck, Matthew ;

Lewis, Mark G. ;

Rinaldi, William ;

Chakraborty, Arup K. ;

Poignard, Pascal ;

Nussenzweig, Michel C. ;

Burton, Dennis R. .

NATURE, 2013, 503 (7475) :224-+

[12] Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys [J].

Borducchi, Erica N. ;

Liu, Jinyan ;

Nkolola, Joseph P. ;

Cadena, Anthony M. ;

Yu, Wen-Han ;

Fischinger, Stephanie ;

Broge, Thomas ;

Abbink, Peter ;

Mercado, Noe B. ;

Chandrashekar, Abishek ;

Jetton, David ;

Peter, Lauren ;

McMahan, Katherine ;

Moseley, Edward T. ;

Bekerman, Elena ;

Hesselgesser, Joseph ;

Li, Wenjun ;

Lewis, Mark G. ;

Alter, Galit ;

Geleziunas, Romas ;

Barouch, Dan H. .

NATURE, 2018, 563 (7731) :360-+

[13] The role of Fc-FcγR interactions in IgG-mediated microbial neutralization [J].

Bournazos, Stylianos ;

DiLillo, David J. ;

Ravetch, Jeffrey V. .

JOURNAL OF EXPERIMENTAL MEDICINE, 2015, 212 (09) :1361-1369

[14] Long-Term Antiretroviral Treatment Initiated at Primary HIV-1 Infection Affects the Size, Composition, and Decay Kinetics of the Reservoir of HIV-1-Infected CD4 T Cells [J].

Buzon, Maria J. ;

Martin-Gayo, Enrique ;

Pereyra, Florencia ;

Ouyang, Zhengyu ;

Sun, Hong ;

Li, Jonathan Z. ;

Piovoso, Michael ;

Shaw, Amy ;

Dalmau, Judith ;

Zangger, Nadine ;

Martinez-Picado, Javier ;

Zurakowski, Ryan ;

Yu, Xu G. ;

Telenti, Amalio ;

Walker, Bruce D. ;

Rosenberg, Eric S. ;

Lichterfeld, Mathias .

JOURNAL OF VIROLOGY, 2014, 88 (17) :10056-10065

[15] Antibody 10-1074 suppresses viremia in HIV-1-infected individuals [J].

Caskey, Marina ;

Schoofs, Till ;

Gruell, Henning ;

Settler, Allison ;

Karagounis, Theodora ;

Kreider, Edward F. ;

Murrell, Ben ;

Pfeifer, Nico ;

Nogueira, Lilian ;

Oliveira, Thiago Y. ;

Learn, Gerald H. ;

Cohen, Yehuda Z. ;

Lehmann, Clara ;

Gillor, Daniel ;

Shimeliovich, Irma ;

Unson-O'Brien, Cecilia ;

Weiland, Daniela ;

Robles, Alexander ;

Kuemmerle, Tim ;

Wyen, Christoph ;

Levin, Rebeka ;

Witmer-Pack, Maggi ;

Eren, Kemal ;

Ignacio, Caroline ;

Kiss, Szilard ;

West, Anthony P., Jr. ;

Mouquet, Hugo ;

Zingman, Barry S. ;

Gulick, Roy M. ;

Keler, Tibor ;

Bjorkman, Pamela J. ;

Seaman, Michael S. ;

Hahn, Beatrice H. ;

Faetkenheuer, Gerd ;

Schlesinger, Sarah J. ;

Nussenzweig, Michel C. ;

Klein, Florian .

NATURE MEDICINE, 2017, 23 (02) :185-191

[16] Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 [J].

Caskey, Marina ;

Klein, Florian ;

Lorenzi, Julio C. C. ;

Seaman, Michael S. ;

West, Anthony P., Jr. ;

Buckley, Noreen ;

Kremer, Gisela ;

Nogueira, Lilian ;

Braunschweig, Malte ;

Scheid, Johannes F. ;

Horwitz, Joshua A. ;

Shimeliovich, Irina ;

Ben-Avraham, Sivan ;

Witmer-Pack, Maggi ;

Platten, Martin ;

Lehmann, Clara ;

Burke, Leah A. ;

Hawthorne, Thomas ;

Gorelick, Robert J. ;

Walker, Bruce D. ;

Keler, Tibor ;

Gulick, Roy M. ;

Faetkenheuer, Gerd ;

Schlesinger, Sarah J. ;

Nussenzweig, Michel C. .

NATURE, 2015, 522 (7557) :487-+

[17] Loss of Infectivity of HIV-1 Particles Produced by Mobile Lymphocytes [J].

Chazal, Maxime ;

Nzounza, Patrycja ;

Pique, Claudine ;

Ramirez, Bertha Cecilia .

PLOS ONE, 2014, 9 (10)

[18] Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses [J].

Chen, Ping ;

Huebner, Wolfgang ;

Spinelli, Matthew A. ;

Chen, Benjamin K. .

JOURNAL OF VIROLOGY, 2007, 81 (22) :12582-12595

[19] Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection [J].

Chun, TW ;

Engel, D ;

Berrey, MM ;

Shea, T ;

Corey, L ;

Fauci, AS .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (15) :8869-8873

[20] Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial [J].

Crowell, Trevor A. ;

Colby, Donn J. ;

Pinyakorn, Suteeraporn ;

Sacdalan, Carlo ;

Pagliuzza, Amelie ;

Intasan, Jintana ;

Benjapornpong, Khunthalee ;

Tangnaree, Kamonkan ;

Chomchey, Nitiya ;

Kroon, Eugene ;

de Souza, Mark S. ;

Tovanabutra, Sodsai ;

Rolland, Morgane ;

Eller, Michael A. ;

Paquin-Proulx, Dominic ;

Bolton, Diane L. ;

Tokarev, Andrey ;

Thomas, Rasmi ;

Takata, Hiroshi ;

Trautmann, Lydie ;

Krebs, Shelly J. ;

Modjarrad, Kayvon ;

McDermott, Adrian B. ;

Bailer, Robert T. ;

Doria-Rose, Nicole ;

Patel, Bijal ;

Gorelick, Robert J. ;

Fullmer, Brandie A. ;

Schuetz, Alexandra ;

Grandin, Pornsuk V. ;

O'Connell, Robert J. ;

Ledgerwood, Julie E. ;

Graham, Barney S. ;

Tressler, Randall ;

Mascola, John R. ;

Chomont, Nicolas ;

Michael, Nelson L. ;

Robb, Merlin L. ;

Phanuphak, Nittaya ;

Ananworanich, Jintanat ;

Ake, Julie ;

Akapirat, Siriwat ;

Bose, Meera ;

Cale, Evan ;

Chan, Phillip ;

Chanthaburanun, Sararut ;

Churikanont, Nampueng ;

Dawson, Peter ;

Dumrongpisutikul, Netsiri ;

Getchalarat, Saowanit .

LANCET HIV, 2019, 6 (05) :E297-E306

← 1 2 3 4 5 6 7 8 9 →